Look Under The Hood: VBK Has 13% Upside

An analysis of the Vanguard Small-Cap Growth ETF (VBK) indicates a weighted average implied analyst target price of $320.74, representing a 13.48% upside from its recent trading price of $282.64. This outlook is bolstered by significant analyst-projected upside in key underlying holdings such as Agilon Health (AGL) at 83.71%, Vimeo (VMEO) at 66.26%, and Neogen Corp (NEOG) at 36.36%. While these figures suggest potential undervaluation within the small-cap growth segment, the analysis also prompts investors to assess the current validity of these analyst targets.

Analysis

An analysis of the Vanguard Small-Cap Growth ETF (VBK) reveals a weighted average implied analyst target price of $320.74, suggesting a potential 13.48% upside from its recent trading price of $282.64. This projection is heavily influenced by significant upside seen in some of its underlying holdings. Notably, Agilon Health (AGL) has an average analyst target 83.71% above its recent price, Vimeo (VMEO) has a 66.26% projected upside, and Neogen Corp (NEOG) shows a 36.36% potential increase. The substantial gap between current trading prices and analyst targets for these key components raises questions about the validity and timeliness of these forecasts. While this points to potential undervaluation within the small-cap growth sector according to analysts, it also introduces a degree of speculation, highlighting the risk that these targets may be overly optimistic or could be subject to future downgrades if company or industry developments do not align with expectations.

Key Decisions for Investors

• Investors considering VBK for small-cap growth exposure should view the 13.48% implied upside as a potential opportunity, but must recognize it is a weighted average heavily influenced by a few high-conviction analyst calls.